IWHM6 | Biocytogen to Present 12 Posters on Innovative Mouse and Rat Models
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) will attend the 6th International Workshop on Humanized Mice (IWHM6) held in Kyoto University, Japan, from October 12 to 14, 2022. The company will present 12 posters on humanized animal models independently developed by its sub brand BioMice, including 8 target humanized mice and 3 second-generation immunodeficient mice/rat models, and the fully human antibody RenMiceTM platform and its derivative platforms.
The conference is expected to have ~300 participants. Renowned immunologist Shimon Sakaguchi will give a plenary lecture on Tregs and the 2012 Nobel Laureate Shinya Yamanaka will give a plenary lecture on iPS cells. In addition, researchers from universities and research institutes in Japan, America and other countries will give talks. In addition to 12 poster presentations, Biocytogen will also exhibit at booth #1. We are excited to introduce more about BioMice!
| Poster Title | Categories | Submission Number |
| 1. Humanized CCR8 mouse model provides a translational tool for anti-human CCR8 antibody drug development | Immunology | #12 |
| 2. Novel hCD3e mouse models for preclinical pharmacology studies of therapeutic bispecific antibodies | Immunology | #13 |
| 3. Developing a translational tool for GLP-1-based therapeutic agonists in humanized GLP1R mice | Other | #14 |
| 4. IL15 and IL2 common receptor humanized mouse models for preclinical studies of novel IL2 and IL15-based therapies | Immunology | #15 |
| 5. Humanized IL36R mice provide a preclinical tool for the evaluation of therapeutic drugs targeting IL36R | Other | #16 |
| 6. Evaluating delivery of TFR1-targeting therapies to the CNS in a novel humanized TFR1 mouse model | Other | #17 |
| 7. Evaluating anti-RANKL antibodies in vivo efficacy on humanized B-hRANKL mice | Other | #23 |
| 8. Evaluating anti-TSLP antibodies in vivo efficacy on humanized B-hTSLP/hTSLPR mice | Other | #24 |
| 9. An in vivo model for human mature NK cells reconstitution to evaluate efficacy of anti-human antibodies by B-NDG hIL15 Mice | Next generation of humanized mice | #25 |
| 10. Development of two novel engineered MHC I and MHC I/II knock-out mouse strains with normal FcRn-mediated antibody retention | Next generation of humanized mice | #26 |
| 11. Development of immunodeficient rat models for simultaneous evaluating drug efficacy and toxicity by B-Rag2 KO rats and B-Rag2/IL2rg KO rats | Next generation of humanized mice | #27 |
| 12. RenMice platforms: Powerful solutions for fully human monoclonal/bispecific/TCR-mimic antibodies discovery | Next generation of humanized mice | #28 |
About BioMice
Driven by technological innovation, Biocytogen has established the “BioMice” brand, which contains the generation, manufacture, supply, and experimental services based on innovative gene-edited animal models. To meet the increasing global demand for genetically modified animal models, Biocytogen has constructed large-scale animal centers in Haimen (Jiangsu) and Daxing (Beijing), China, with a satellite facility in Boston, USA. With a wide range of animal strains, large-scale supply capabilities, and high-quality service, BioMice has been recognized as a long-term partner by many domestic and overseas research institutes and pharmaceutical companies.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company’s pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 02315.HK. For more information, please visit http://en.biocytogen.com.cn.
